Filing Flows › Castle Biosciences (CSTL) › Q3 2026 › vs Q3 2025
Castle Biosciences (CSTL) Q3 2026 vs Q3 2025 (year over year)
Castle Biosciences's revenue rose $19.8M (+24%) from $83.0M in Q3 2025 to $103M in Q3 2026. The biggest changes: Non-Dermatologic +$20.5M (+59%); Dermatologic −$646K (-1%).
Castle Biosciences, Q3 2026: revenue $103M (+24% year over year), operating margin -2.7%, net loss $4.1M, operating cash flow $19.7M. The chart draws each line against Q3 2025, the increases inside each band.
Margins
| Q3 2026 | Q3 2025 | Change | |
|---|---|---|---|
| Free cash flow margin | 11.9% | 9.4% | +2.5 pts |
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Non-Dermatologic | $55.0M | $34.5M | $20.5M | +59% |
| Dermatologic | $47.9M | $48.5M | −$646K | -1% |
| Revenue | $103M | $83.0M | $19.8M | +24% |
| Net loss | $4.1M | $501K | $3.6M | +718% |
| Costs & expenses | $107M | $90.0M | $17.0M | +19% |
| Operating costs | $106M | $89.8M | $15.8M | +18% |
| Interest & other, net | $1.1M | −$6.4M | $7.5M | — |
| Income tax | $298K | $115K | $183K | +159% |
| Cost of revenue | $23.9M | $18.7M | $5.2M | +28% |
| Research & development | $15.8M | $13.0M | $2.8M | +22% |
| SG&A | $63.8M | $55.9M | $7.9M | +14% |
| Other operating costs | $2.1M | $2.3M | −$172K | -8% |
| Operating cash sources | $23.8M | $23.1M | $709K | +3% |
| Depreciation & amortization | $4.2M | $3.8M | $363K | +10% |
| Share-based compensation | $11.2M | $12.1M | −$868K | -7% |
| Working capital & other | $8.4M | $7.2M | $1.2M | +17% |
| Net loss absorbed | $4.1M | $501K | $3.6M | +718% |
| Operating cash flow | $19.7M | $22.6M | −$2.9M | -13% |
| Free cash flow (OCF − capex) | $12.2M | $7.8M | $4.5M | +57% |
| Capital expenditures | $7.5M | $14.8M | −$7.3M | -49% |
Questions
How much did Castle Biosciences's revenue grow year over year in Q3 2026?
Castle Biosciences's revenue rose $19.8M (+24%) from $83.0M in Q3 2025 to $103M in Q3 2026.
What drove Castle Biosciences's revenue change in Q3 2026?
Non-Dermatologic +$20.5M (+59%); Dermatologic −$646K (-1%).